
Advertise on podcast: PRISM Rounds: Pulmonary Critical Care & Sleep Medicine Podcast
Rating
5from
This podcast has
67 episodes
Language
EnglishPublisher
@bronchoscopeExplicit
No
Date created
2026/02/09
Latest episode
2026/11/11
Average duration
41 min.
Release period
7 days
Description
PRISM Rounds is a clinical review series by the PRISM research team. Every other week, we break down a high-impact Pulmonary, Critical Care, or Sleep article into three segments: The Blueprint: Study design and methodology. The Math: Demystifying the statistics. The "So What?": Real-world bedside implications. We bridge the gap between the journal and the clinic/ICU, helping you interpret trials quickly and skip the noise. Learn more about our research and clinical trials at: https://www.prismtrials.com/ For questions and suggestions contact: [email protected]
Unlock PRISM Rounds: Pulmonary Critical Care & Sleep Medicine Podcast podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from PRISM Rounds: Pulmonary Critical Care & Sleep Medicine Podcast podcast
S01E66 | ICRAKI: Intermittent vs Continuous Dialysis. Does Modality Affect Survival?
2026/11/11
When a critically ill patient needs dialysis, does the initial treatment modality affect survival?
In this episode of PRISM Rounds, we examine the ICRAKI trial, published in the New England Journal of Medicine, comparing initial intermittent hemodialysis with continuous renal replacement therapy in critically ill adults with acute kidney injury.
Intermittent dialysis did not establish noninferiority for major adverse kidney events at 90 days. Mortality was higher in the intermittent group, 63.1% versus 53.5%, and the trial stopped early after sustained mortality concerns. We explore why this signal matters, how early stopping and the statistical testing framework affect interpretation, and why failure to demonstrate noninferiority does not establish superiority on the primary outcome.
We discuss:• The population studied and applicability to patients receiving vasopressors.• The primary composite of death, dialysis dependence, and impaired kidney function.• Treatment crossover, hemodynamic tolerance, and uncertainty about the mortality difference.• What these findings may mean for initial dialysis decisions at the bedside.
For the next stage of kidney support, revisit S01E04 on the LIBERATE-D trial, which examined an indication-based dialysis strategy in hemodynamically stable patients recovering from acute kidney injury.
Primary article:https://doi.org/10.1056/NEJMoa2608397
Accompanying editorial:https://doi.org/10.1056/NEJMe2612910
Related episode, LIBERATE-D:https://podcasts.apple.com/us/podcast/id1875937459?i=1000749045576
Follow PRISM Rounds on Apple Podcasts, Spotify, and YouTube, or visit https://www.prismrounds.com. Share this episode with a colleague and tell us how your team approaches dialysis modality selection.
This episode uses AI-generated voices with clinician-curated content. Educational use only; not individual medical advice.
Tags:
ICRAKI, acute kidney injury, AKI, dialysis, intermittent hemodialysis, continuous renal replacement therapy, CRRT, kidney replacement therapy, renal recovery, critical care, intensive care, ICU, nephrology, hemodynamic instability, vasopressors, randomized controlled trial, noninferiority, evidence based medicine, journal club, NEJM, LIBERATE-D, PRISM Rounds
S01E65 | TRICYCLE Trial: Early Multimodal Vasopressors in Septic Shock
2026/11/06
When a patient with septic shock requires escalating norepinephrine, should we continue increasing the dose, or introduce multiple vasopressors earlier?
In this episode of PRISM Rounds, we examine the TRICYCLE randomized controlled trial, published in Critical Care in 2026, which evaluated early multimodal vasopressor therapy combining norepinephrine, vasopressin, and angiotensin II versus conventional stepwise escalation.
The 79-patient trial found faster reductions in plasma renin and lactate, earlier reductions in vasopressor requirements, improved organ dysfunction scores, and fewer tachyarrhythmias. However, a survival benefit was not established, and the trial was not powered to detect differences in mortality.
We explore several important questions:
Why target three vasoconstrictor pathways instead of one?
Is renin a useful biomarker or simply a reflection of angiotensin II activity?
Does earlier catecholamine sparing translate into meaningful clinical benefit?
Was TRICYCLE truly an early-intervention trial, or were patients already receiving substantial vasopressor support?
Should these findings change how we manage septic shock today?
We also examine the methodological debate surrounding the trial and place its findings in the context of prior vasopressor research.
The bedside bottom line: TRICYCLE offers promising physiological evidence for multimodal vasopressor therapy, but larger trials are needed before routine early triple therapy can be recommended.
Featured publication:Kalamar et al. Early multimodal vasopressor strategy in septic shock: results of the TRICYCLE randomized controlled trial. Critical Care. 2026;30:508.
https://doi.org/10.1186/s13054-026-06323-z
PRISM Rounds uses AI-generated voices, with content curated for clinical accuracy and educational value. Episodes are intended for education and discussion, not individual medical advice.
#PRISMRounds #TRICYCLETrial #SepticShock #Sepsis #CriticalCare #IntensiveCare #Vasopressors #Norepinephrine #Vasopressin #AngiotensinII #Hemodynamics #ClinicalTrials #EvidenceBasedMedicine #ICUResearch #PulmonaryCriticalCare
S01E64 | VASSPR Trial: Does Earlier Vasopressin Save Lives in Septic Shock?
2026/10/28
When should we add vasopressin in septic shock? At a norepinephrine dose of 0.1 mcg/kg/min, or should we wait until 0.4?
In this episode of PRISM Rounds, we examine the VASSPR trial, published in JAMA in October 2026. This pragmatic, cluster-randomized crossover trial enrolled 3,959 patients across 13 hospitals and compared earlier versus later vasopressin initiation strategies.
Earlier initiation increased vasopressin use and reduced the norepinephrine dose at which it was started. However, 28-day mortality was similar between groups (31.8% vs 33.0%), with no significant improvement in kidney replacement therapy-free days.
We explore the trial's strengths, imperfect adherence, implications for current sepsis guidelines, and why a fixed norepinephrine threshold may not capture the complexity of septic shock.
The central question: Should vasopressor management be guided by a number, or by the patient's evolving physiology?
A practical, evidence-based discussion for intensivists, emergency physicians, hospitalists, fellows, nurses, and ICU pharmacists.
Primary article: Peltan ID, et al. Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial. JAMA. October 14, 2026.
https://doi.org/10.1001/jama.2026.21333
Tags: Septic Shock, VASSPR Trial, Vasopressin, Norepinephrine, Critical Care, Intensive Care, Sepsis, Vasopressors, Hemodynamics, JAMA, Clinical Trials, Evidence-Based Medicine, PRISM Rounds
At PRISM Rounds, we use AI-generated voices to bring you thoughtfully curated medical research in an engaging, conversational format. While we do our best to keep things accurate, occasional errors or mispronunciations may slip through. We hope these episodes spark curiosity and encourage you to explore the original research.
S01E63 | Oveporexton for Narcolepsy Type 1: A New Approach to Wakefulness and Cataplexy
2026/10/23
Can stimulating the orexin receptor improve both sleepiness and cataplexy in narcolepsy type 1? In this episode of PRISM Rounds, we examine the First Light and Radiant Light phase 3 trials of oveporexton.
Across two 12-week trials, oveporexton produced substantial improvements in objective wakefulness, patient-reported sleepiness, and cataplexy compared with placebo. We discuss what those changes could mean for patients, why urinary frequency and insomnia matter, and what remains uncertain about long-term safety and comparisons with existing treatments.
Read the trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2601598
Find more episodes at https://www.prismrounds.com and follow PRISM Rounds on Spotify or Apple Podcasts.
Tags
narcolepsy type 1, oveporexton, orexin, hypocretin, cataplexy, excessive daytime sleepiness, sleep medicine, clinical trials, First Light trial, Radiant Light trial, NEJM, PRISM Rounds
S01E62 | High-Flow Oxygen vs NIV: What the New 2026 ATS Guidelines Recommend
2026/10/16
Choosing between high-flow nasal cannula, noninvasive ventilation (NIV), CPAP, and conventional oxygen is one of the most common decisions in critical care. The new 2026 American Thoracic Society (ATS) Clinical Practice Guideline provides updated, evidence-based recommendations across the spectrum of acute respiratory failure.
In Season 1, Episode 62 of PRISM Rounds, we examine the guideline published in the American Journal of Respiratory and Critical Care Medicine and explore what its recommendations mean for bedside practice.
We discuss four critical clinical questions:
Acute hypoxemic respiratory failure: Why is high-flow nasal cannula strongly recommended over conventional oxygen, and when should clinicians consider NIV or CPAP?
Acute hypercapnic respiratory failure: Why does NIV remain first-line therapy, and when might high-flow oxygen be a reasonable alternative?
Preoxygenation before intubation: How can HFNC and NIV reduce peri-intubation hypoxemia?
Postextubation respiratory support: Which patients benefit from preventive NIV or HFNC, and how can we reduce reintubation?
We also examine the strength and certainty of the evidence, important limitations of network meta-analyses, and the distinction between reducing intubation and improving survival.
The central clinical question: Are we choosing the right respiratory support strategy for the right patient, and recognizing early enough when that strategy is failing?
This episode is designed for intensivists, pulmonologists, emergency physicians, respiratory therapists, critical care fellows, and other clinicians managing acute respiratory failure.
Primary Reference:Goel NN, Ferreyro BL, et al. Noninvasive respiratory support for adult patients with acute respiratory failure: An official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 2026;212(9):2135–2158.
https://doi.org/10.1093/ajrccm/aamag302
Listen and subscribe to PRISM Rounds on Apple Podcasts, Spotify, Youtube or visit https://www.prismrounds.com.
Evidence reviewed. Clinical decisions informed.
Tags
ritical Care
Pulmonary Medicine
ATS Guidelines
Noninvasive Ventilation
NIV
High-Flow Nasal Cannula
HFNC
CPAP
Acute Respiratory Failure
Hypoxemic Respiratory Failure
Hypercapnic Respiratory Failure
COPD Exacerbation
Mechanical Ventilation
Preoxygenation
Extubation
Intensive Care Medicine
Evidence-Based Medicine
Clinical Practice Guidelines
Respiratory Therapy
PRISM Rounds
S01E61 | Plasma Exchange in Acute-on-Chronic Liver Failure: Buying Time or Saving Lives?
2026/10/11
Can therapeutic plasma exchange save lives in acute-on-chronic liver failure, or does it simply delay the inevitable?
In Season 1, Episode 61 of PRISM Rounds, we examine a 2026 randomized controlled trial published in Hepatology evaluating therapeutic plasma exchange in 194 patients with acute-on-chronic liver failure (ACLF).
The findings are striking. Plasma exchange reduced 28-day mortality from 63.9% to 44.3%, an absolute difference of nearly 20 percentage points. However, by 90 days, mortality was similar between groups, and more than 40% of patients could not complete the planned treatment.
We examine the trial's methodology, treatment complications, and clinical implications alongside the 2023 EASL guidelines and a 2025 meta-analysis of plasma exchange in ACLF.
The central question: Does plasma exchange meaningfully alter the course of liver failure, or does it provide a temporary bridge to hepatic recovery or transplantation?
Join us as we explore what this trial should, and should not, change in ICU practice.
Read the primary study:https://doi.org/10.1097/HEP.0000000000001755
Subscribe to PRISM Rounds on Apple Podcasts, Spotify, or YouTube.
Visit https://www.prismrounds.com for more episodes.
Tags
Critical Care, Intensive Care, Hepatology, Acute-on-Chronic Liver Failure, ACLF, Therapeutic Plasma Exchange, Plasmapheresis, Liver Failure, Liver Transplantation, Randomized Controlled Trial, Evidence-Based Medicine, ICU Research, PRISM Rounds
S01E60: Olanzapine vs Dexmedetomidine for ICU Delirium
2026/10/04
In this episode of PRISM Rounds, we examine a new randomized clinical trial comparing olanzapine with low-dose dexmedetomidine for established delirium in critically ill adults.
The primary outcome was neutral: patients in both groups had a median of 3 days alive without delirium or coma. But the study also found more adverse events with dexmedetomidine and a provocative difference in 90-day mortality that demands careful interpretation.
We place these findings in the context of MIND-USA, AID-ICU, SPICE III, nocturnal dexmedetomidine studies, and the 2025 PADIS guideline update. The key issue is not simply which drug performed better, but whether ICU clinicians are asking medications to do different jobs: prevent delirium, control agitation, or actually treat established delirium.
We discuss what this trial adds, its major limitations, why the mortality signal should remain hypothesis-generating, and what the results should—and should not—change at the bedside.
Primary article:https://doi.org/10.1093/ajrccm/aamag235
Listen and subscribe on Apple Podcasts, Spotify, YouTube, or at https://www.prismrounds.com
PRISM Rounds, critical care, ICU, delirium, ICU delirium, dexmedetomidine, olanzapine, antipsychotics, sedation, agitation, PADIS, MIND-USA, AID-ICU, SPICE III, mechanical ventilation, intensive care medicine, pulmonary critical care, evidence based medicine, journal club, randomized controlled trial, FOAMcc, FOAMed
Tags
S01E59 | ICECAP :Does Longer Cooling Improve Recovery After Cardiac Arrest?
2026/09/26
How long should comatose patients remain at 33°C after out-of-hospital cardiac arrest?
In this episode of PRISM Rounds, we examine the icecap randomized clinical trial, which studied 1,158 comatose OHCA survivors who had already been rapidly cooled to 33°C. Patients were assigned to different cooling durations ranging from 6 to 72 hours.
Longer cooling did not improve neurological recovery, mortality, or secondary neurological outcomes. We discuss the adaptive trial design, the separate shockable and nonshockable rhythm cohorts, the meaning of the approximately 50% probability that 6 hours was the shortest optimal duration, and why this does not establish a universal six-hour protocol.
The episode places icecap in context with TTM, TTM2, and HYPERION while keeping clear that these trials addressed different temperature-management questions.
Read the study:https://jamanetwork.com/journals/jama/fullarticle/2852508
Subscribe to PRISM Rounds on Apple Podcasts, Spotify, or YouTube, and visit:https://www.prismrounds.com
Tags:icecap, cardiac arrest, out-of-hospital cardiac arrest, OHCA, targeted temperature management, therapeutic hypothermia, post-cardiac arrest care, neuroprotection, neurological recovery, TTM, TTM2, HYPERION, critical care, intensive care, emergency medicine, resuscitation, ICU, fever prevention, modified Rankin Scale, PRISM Rounds
S01E58: SCCM Heat Stroke Guidelines - Cool Fast, Treat Smart
2026/09/17
In Season 1, Episode 58 of PRISM Rounds, we review the 2025 Society of Critical Care Medicine guideline for the treatment of heat stroke and translate its recommendations into practical bedside decisions for emergency and critical care clinicians.
We discuss why active cooling should begin immediately, why cold- or ice-water immersion is preferred when feasible, and why the guideline emphasizes both the speed of cooling and the goal of reaching a core temperature below about 39°C within 30 minutes. We also review what to do when immersion is not practical and how the guideline approaches classic versus exertional heat stroke.
The episode also covers therapies that should generally be avoided. Routine acetaminophen, NSAIDs, salicylates, and dantrolene are not recommended for temperature reduction, and prophylactic antibiotics or antiseizure medications should be limited to research settings.
An important theme is the strength of the recommendations versus the strength of the evidence. Several recommendations are strong despite very low-certainty evidence, reflecting the practical and ethical difficulty of conducting randomized trials that delay effective cooling in patients with true heat stroke.
The bedside message is simple: recognize heat stroke early, start the fastest feasible active cooling strategy, continue simultaneous resuscitation and organ support, and avoid medications that do not address the underlying problem.
Read the guideline:https://doi.org/10.1097/CCM.0000000000006551
More PRISM Rounds:https://www.prismrounds.com
Available on Apple Podcasts, Spotify, YouTube, and other major podcast platforms.
Tags:PRISM Rounds, S01E58, critical care, ICU, heat stroke, heatstroke, hyperthermia, SCCM, Society of Critical Care Medicine, emergency medicine, cooling, cold water immersion, ice water immersion, exertional heat stroke, classic heat stroke, temperature management, dantrolene, antipyretics, heat illness, resuscitation, evidence based medicine, clinical guidelines, guideline review, medical education, FOAMed, pulmonary critical care
S01E57 | PRAGUE-26: Early Catheter-Directed Thrombolysis for Intermediate-High-Risk Pulmonary Embolism
2026/09/09
Should we wait for a patient with intermediate-high-risk pulmonary embolism to deteriorate before pursuing reperfusion—or intervene before the right ventricle fails?
In this episode of PRISM Rounds, we examine PRAGUE-26, a multicenter randomized trial published in the New England Journal of Medicine comparing conventional catheter-directed thrombolysis with low-dose alteplase plus anticoagulation against anticoagulation alone in patients with intermediate-high-risk acute pulmonary embolism.
The headline result is striking: the 7-day composite of death, recurrent pulmonary embolism, or cardiorespiratory decompensation or collapse occurred in 0.7% with catheter-directed thrombolysis versus 6.8% with standard care. But the interpretation requires nuance. The benefit was driven primarily by fewer episodes of cardiorespiratory deterioration, not a demonstrated mortality reduction. Overall major bleeding was not clearly increased, yet two intracranial hemorrhages occurred in the thrombolysis group and none with anticoagulation alone.
We break down patient selection, the low-dose alteplase strategy, the composite endpoint, rescue reperfusion, early RV recovery, bleeding risk, and the limitations of an open-label trial conducted in experienced tertiary cardiovascular centers. Most importantly, we ask what prague-26 should change at the bedside: Does this trial support routine early catheter-directed thrombolysis, or does it help us identify the selected patient who should undergo reperfusion before overt hemodynamic collapse?
The article was published online in the New England Journal of Medicine on August 31, 2026, DOI 10.1056/NEJMoa2608012.
PRISM Trials / PRISM Rounds:
Visit PRISM Trials
Journal article:
Read “Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism” in NEJM
Tags:
#PRISMRounds #PRISMTrials #CriticalCare #CriticalCareMedicine #ICU #PulmonaryCriticalCare #PulmonaryMedicine #Pulmonology #PulmonaryEmbolism #PE #IntermediateHighRiskPE #SubmassivePE #CatheterDirectedThrombolysis #CDT #Thrombolysis #Alteplase #Anticoagulation #Reperfusion #PERT #PulmonaryEmbolismResponseTeam #RightVentricle #RVFailure #RightHeartStrain #HemodynamicCollapse #CardiorespiratoryDecompensation #Shock #VTE #VenousThromboembolism #EmergencyMedicine #Cardiology #InterventionalCardiology #IntensiveCare #ClinicalTrials #RandomizedTrial #RCT #EvidenceBasedMedicine #MedicalEducation #JournalClub #NEJM #FOAMed #FOAMcc #MedEd #EvidenceBasedCriticalCare
S01E56 SAVE-O2 AI: Can Oxygen Titrate Itself Better Than We Can?
2026/09/04
In this episode of PRISM Rounds, we discuss the SAVE-O2 AI randomized clinical trial, which tested autonomous closed-loop oxygen titration versus usual manual oxygen adjustment in 300 hospitalized adults receiving supplemental oxygen.
The autonomous system kept patients in the target SpO2 range much more often, 85% vs 63%, while also reducing time spent in hypoxemia and, even more strikingly, hyperoxemia. We break down what the trial shows, what it does not show, the importance of pulse oximetry accuracy and skin pigmentation, and whether improved oxygen control is enough to justify broader implementation.
We also discuss the accompanying editorial by Weingart and Matthay, which explores the potential impact on clinician workload, oxygen stewardship, resource-limited settings, and the next generation of implementation and outcomes studies.
SAVE-O2 AI trial, JAMA Internal Medicinehttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.4023DOI: https://doi.org/10.1001/jamainternmed.2026.4023
Invited Commentary: Potential Transformative Impact of Autonomous Oxygen Delivery in Hospitalized Patientshttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.4038DOI: https://doi.org/10.1001/jamainternmed.2026.4038
Find more episodes at www.prismrounds.com and subscribe on Apple Podcasts or Spotify.
Tags#PRISMRounds #SAVE02AI #CriticalCare #ICU #PulmonaryCriticalCare #OxygenTherapy #Hypoxemia #Hyperoxemia #PulseOximetry #ClosedLoopControl #ArtificialIntelligence #DigitalHealth #ClinicalTrials #RandomizedTrial #JAMAInternalMedicine #RespiratoryCare #FOAMcc #MedEd
S01E55 | Video Laryngoscopy in the OR: The COVALENT Trial
2026/08/28
Does video laryngoscopy improve first pass success for routine tracheal intubation, and does blade geometry matter?
In this episode of PRISM Rounds, we discuss the COVALENT randomized clinical trial, which compared direct laryngoscopy, Macintosh style video laryngoscopy, and hyperangulated video laryngoscopy in more than 2,400 perioperative intubations.
We review the higher first pass success with video laryngoscopy, why the hyperangulated strategy performed best, the important role of stylet use, and what the accompanying editorial adds to the interpretation.
We also discuss how COVALENT builds on the DEVICE trial in critically ill adults and why the airway conversation may now be shifting from simply video versus direct toward which video strategy, blade, and adjunct work best in different clinical settings.
Find PRISM Rounds on Apple Podcasts, Spotify, and https://prismrounds.com
Tags:Critical Care, ICU, Airway Management, Video Laryngoscopy, Direct Laryngoscopy, COVALENT Trial, DEVICE Trial, Tracheal Intubation, First Pass Success, Emergency Airway, Anesthesiology, Pulmonary Critical Care, Evidence Based Medicine, Journal Club, PRISM Rounds, FOAMcc, FOAMed
S01E54: Rocuronium Dose and First-Pass Success: Are We Giving Enough?
2026/08/24
DescriptionWe obsess over the paralytic, but are we giving enough of it?
In this episode of PRISM Rounds, we review a new AJRCCM secondary analysis of 1,822 critically ill adults from the DEVICE and PREOXI trials examining whether rocuronium dose is associated with first-attempt intubation success.
Patients receiving more than 1.2 mg/kg had higher first-attempt success overall, with the strongest signal in ICU patients. But rocuronium dose was chosen by clinicians rather than randomized, so residual confounding matters.
We break down the study, the accompanying editorial, the pharmacologic rationale for higher dosing, the ICU versus ED findings, and the key bedside question: Should this change how we dose rocuronium during emergency intubation?
Original article:https://academic.oup.com/ajrccm/article/212/8/1740/8679093
Accompanying editorial:https://academic.oup.com/ajrccm/article/212/8/1680/8706698
Educational use only. This is not medical advice.
TagsCritical Care, ICU, Airway Management, Tracheal Intubation, Emergency Intubation, Rocuronium, Neuromuscular Blockade, Rapid Sequence Intubation, RSI, First Pass Success, First Attempt Success, Video Laryngoscopy, DEVICE Trial, PREOXI Trial, AJRCCM, Pulmonary Critical Care, Emergency Medicine, Anesthesiology, Evidence Based Medicine, Journal Club, Medical Education, PRISM Rounds
S1E53 | SynAIRgy: The First Pill for Sleep Apnea? A Phase 3 Trial of AD109
2026/08/16
Could a bedtime pill become a meaningful treatment for obstructive sleep apnea?In PRISM Rounds Season 1, Episode 53, we examine “Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy).”This randomized, double-blind, placebo-controlled trial evaluated AD109, an investigational combination of aroxybutynin and atomoxetine, in adults with obstructive sleep apnea who could not or would not use positive airway pressure therapy.AD109 improved the apnea-hypopnea index and measures of oxygenation over 26 weeks. However, the average placebo-adjusted reduction was four respiratory events per hour, fatigue did not significantly improve compared with placebo, and approximately one in five participants discontinued treatment because of adverse effects.We discuss:• How AD109 is intended to improve upper-airway muscle function• The trial design and primary findings• Relative versus absolute reductions in the apnea-hypopnea index• Intention-to-treat versus on-treatment results• Hypoxic burden and changes in sleep architecture• Insomnia, dry mouth, tachycardia, and treatment discontinuation• Which patients might benefit if AD109 is approved• Why CPAP remains the most effective and best-established treatment for most patientsDoes SynAIRgy represent the beginning of oral precision therapy for sleep apnea, and can better phenotyping identify patients whose benefits outweigh the adverse effects?Primary article: https://doi.org/10.1093/ajrccm/aamag215Accompanying editorial: https://doi.org/10.1093/ajrccm/aamag243PRISM Rounds is intended for education and discussion and does not provide medical advice.Tags: PRISM Rounds, SynAIRgy, AD109, aroxybutynin, atomoxetine, obstructive sleep apnea, OSA, sleep apnea treatment, sleep medicine, CPAP, positive airway pressure, apnea-hypopnea index, AHI, hypoxic burden, randomized clinical trial, phase 3 trial, AJRCCM, pulmonary medicine, clinical research, medical education, FOAMed#PRISMRounds #SynAIRgy #AD109 #SleepApnea #OSA #SleepMedicine #CPAP #ClinicalTrials #PulmonaryMedicine #MedicalEducation #FOAMed
S01E52: The LOGICAL Trial | Conservative Oxygen After Cardiac Arrest
2026/08/06
Should oxygen be aggressively limited after cardiac arrest to reduce reperfusion injury?The LOGICAL trial randomized 1,840 unresponsive, mechanically ventilated adults after cardiac arrest to conservative or liberal oxygen therapy. Favorable functional outcomes at 180 days occurred in 38.2% versus 39.7%, with no significant difference between strategies.In this episode, we examine the trial design, oxygen targets, treatment separation, protocol deviations, key results, limitations, and practical implications for post-cardiac arrest care.Read the article in the New England Journal of Medicine:https://doi.org/10.1056/NEJMoa2513814Educational use only. This is not medical advice.Tags:LOGICAL trial, cardiac arrest, post cardiac arrest care, oxygen therapy, conservative oxygen, hyperoxemia, hypoxemia, reperfusion injury, critical care, intensive care, ICU, mechanical ventilation, resuscitation, neurocritical care, NEJM, Mega-ROX, evidence based medicine, journal club, pulmonary critical care, PRISM Rounds
Podcast reviews
Read PRISM Rounds: Pulmonary Critical Care & Sleep Medicine Podcast podcast reviews
Podcast sponsorship advertising
Start advertising on PRISM Rounds: Pulmonary Critical Care & Sleep Medicine Podcast relevant audience podcasts
You may also like to advertise on these Podcasts

4.920911196
Toni and Ryan
Toni Lodge and Ryan Jon

4.6652752197
The Charlie Kirk Show
Charlie Kirk

4.8167482000
The GaryVee Audio Experience
Gary Vaynerchuk

4.827591720
Earn Your Happy
Lori Harder | YAP Media

4.762632000
The Lawfare Podcast
The Lawfare Institute

4.715161997
Thrivetime Show | Business School without the BS
Clay Clark

4.98711800
The Adam Mockler Show
MeidasTouch Network

4.619842891
All Ears English Podcast
Lindsay McMahon and Michelle Kaplan

4.82494975
The 1000 Hours Outside Podcast
1000 Hours Outside

4.824781904
Deck The Hallmark
Bramble Jam Podcast Network